Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Tevogen Bio (Nasdaq: TVGN) announced that Founder and CEO Ryan Saadi has been named to the 2025 NJBIZ Power 100, recognizing influential figures in New Jersey's business landscape. The clinical-stage specialty immunotherapy biotech company is developing affordable T cell therapies for viral infections and cancers.
The company's proprietary ExacTcell™ technology has demonstrated positive results in a proof-of-concept trial, with findings published in Blood Advances. A significant advancement in making therapies more accessible was marked by the launch of Tevogen.AI and a partnership with Microsoft.
Dr. Saadi, honored alongside Johnson & Johnson CEO Joaquin Duato, emphasized that this recognition reflects Tevogen's mission to challenge traditional biotech models by focusing on affordability, accessibility, and sustainability in drug development.
Tevogen Bio (Nasdaq: TVGN) ha annunciato che il Fondatore e CEO Ryan Saadi è stato nominato nella 2025 NJBIZ Power 100, riconoscendo figure influenti nel panorama imprenditoriale del New Jersey. L'azienda biotecnologica specializzata in immunoterapia in fase clinica sta sviluppando terapie cellulari T accessibili per infezioni virali e tumori.
La tecnologia proprietaria ExacTcell™ dell'azienda ha dimostrato risultati positivi in uno studio di prova di concetto, con risultati pubblicati su Blood Advances. Un significativo passo avanti nel rendere le terapie più accessibili è stato segnato dal lancio di Tevogen.AI e da una partnership con Microsoft.
Il Dr. Saadi, onorato insieme al CEO di Johnson & Johnson Joaquin Duato, ha sottolineato che questo riconoscimento riflette la missione di Tevogen di sfidare i modelli tradizionali delle biotecnologie, concentrandosi su accessibilità, sostenibilità e convenienza nello sviluppo di farmaci.
Tevogen Bio (Nasdaq: TVGN) anunció que el Fundador y CEO Ryan Saadi ha sido nombrado en la 2025 NJBIZ Power 100, reconociendo a figuras influyentes en el panorama empresarial de Nueva Jersey. La empresa biotecnológica especializada en inmunoterapia en etapa clínica está desarrollando terapias de células T asequibles para infecciones virales y cánceres.
La tecnología propietaria ExacTcell™ de la empresa ha demostrado resultados positivos en un ensayo de prueba de concepto, con hallazgos publicados en Blood Advances. Un avance significativo en la accesibilidad de las terapias se marcó con el lanzamiento de Tevogen.AI y una asociación con Microsoft.
El Dr. Saadi, honrado junto al CEO de Johnson & Johnson, Joaquin Duato, enfatizó que este reconocimiento refleja la misión de Tevogen de desafiar los modelos tradicionales de biotecnología al centrarse en la asequibilidad, accesibilidad y sostenibilidad en el desarrollo de medicamentos.
Tevogen Bio (Nasdaq: TVGN)는 창립자이자 CEO인 Ryan Saadi가 2025 NJBIZ Power 100에 이름을 올렸다고 발표했습니다. 이는 뉴저지 비즈니스 환경에서 영향력 있는 인물들을 인정하는 것입니다. 이 임상 단계의 전문 면역 치료 생명공학 회사는 바이러스 감염 및 암에 대한 저렴한 T 세포 치료법을 개발하고 있습니다.
회사의 독점 기술인 ExacTcell™은 혈액 발전(Blood Advances)에 발표된 결과와 함께 개념 증명 시험에서 긍정적인 결과를 보여주었습니다. 치료법의 접근성을 높이는 데 있어 중요한 진전을 이룬 것은 Tevogen.AI의 출시와 Microsoft와의 파트너십으로 나타났습니다.
Saadi 박사는 Johnson & Johnson의 CEO인 Joaquin Duato와 함께 이 영예를 안으며, 이 인정이 Tevogen의 사명이 전통적인 생명공학 모델에 도전하고 약물 개발에서의 접근성, 지속 가능성 및 저렴함에 중점을 두고 있음을 반영한다고 강조했습니다.
Tevogen Bio (Nasdaq: TVGN) a annoncé que le fondateur et PDG Ryan Saadi a été nommé dans le 2025 NJBIZ Power 100, reconnaissant des figures influentes dans le paysage commercial du New Jersey. Cette entreprise biopharmaceutique spécialisée dans l'immunothérapie en phase clinique développe des thérapies cellulaires T abordables pour les infections virales et les cancers.
La technologie propriétaire ExacTcell™ de l'entreprise a montré des résultats positifs lors d'un essai de preuve de concept, avec des résultats publiés dans Blood Advances. Un progrès significatif dans l'accessibilité des thérapies a été marqué par le lancement de Tevogen.AI et un partenariat avec Microsoft.
Le Dr Saadi, honoré aux côtés du PDG de Johnson & Johnson, Joaquin Duato, a souligné que cette reconnaissance reflète la mission de Tevogen de défier les modèles biotechnologiques traditionnels en se concentrant sur l'accessibilité, la durabilité et l'abordabilité dans le développement de médicaments.
Tevogen Bio (Nasdaq: TVGN) gab bekannt, dass der Gründer und CEO Ryan Saadi in die 2025 NJBIZ Power 100 aufgenommen wurde, die einflussreiche Persönlichkeiten in der Geschäftswelt von New Jersey anerkennt. Das biopharmazeutische Unternehmen, das sich auf klinische Immuntherapien spezialisiert hat, entwickelt erschwingliche T-Zell-Therapien für Virusinfektionen und Krebs.
Die proprietäre ExacTcell™-Technologie des Unternehmens hat in einer Machbarkeitsstudie positive Ergebnisse gezeigt, deren Ergebnisse in Blood Advances veröffentlicht wurden. Ein bedeutender Fortschritt in der Zugänglichkeit von Therapien wurde mit der Einführung von Tevogen.AI und einer Partnerschaft mit Microsoft markiert.
Dr. Saadi, der zusammen mit Johnson & Johnson CEO Joaquin Duato geehrt wurde, betonte, dass diese Auszeichnung die Mission von Tevogen widerspiegelt, traditionelle Biotech-Modelle herauszufordern, indem sie sich auf Erschwinglichkeit, Zugänglichkeit und Nachhaltigkeit in der Arzneimittelentwicklung konzentriert.
- None.
- None.
- Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.
- The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood Advances.
- A key step in making therapies more accessible was the launch of Tevogen.AI and a partnership with Microsoft.
WARREN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, announced today that its Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 NJBIZ Power 100, recognizing the most influential figures shaping New Jersey’s business landscape. The editorial team at NJBIZ highlights honorees as strategic leaders and innovators who drive progress and represent the state’s diversity.
Dr. Saadi leads Tevogen Bio in its mission to develop the affordable, safe, and easy-to-administer T cell therapy for acute viral infections, the long-term effects of viral infections, and both viral and non-viral induced cancers. By leveraging the company’s proprietary ExacTcell technology, designed to address accessibility challenges, a proof-of-concept trial was completed with highly positive results, and the findings have been published in Blood Advances. A major milestone in Tevogen’s quest to make therapies more accessible was the recent launch of Tevogen.AI, along with its partnership with Microsoft.
Dr. Saadi emphasized that this recognition reflects Tevogen Bio’s unique mission rather than personal achievement. “Tevogen represents a new category of biotech, one designed to challenge the rising costs of drug development with a highly efficient and scalable business model,” said Dr. Saadi. “I am honored to be named alongside leaders such as Joaquin Duato (CEO of Johnson & Johnson), and hope to continue to defy conventional biotech expectations, prioritizing affordability, accessibility, and long-term sustainability.”
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What are the key achievements of Tevogen Bio (TVGNW) in 2025?
How is Tevogen Bio (TVGNW) making T cell therapy more accessible?
What therapeutic areas does Tevogen Bio (TVGNW) target with its T cell therapy?
What recent clinical validation has Tevogen Bio (TVGNW) received?
How does Tevogen Bio (TVGNW) differentiate itself from traditional biotech companies?
